HFCAS OpenIR

浏览/检索结果: 共4条,第1-4条 帮助

限定条件            
已选(0)清除 条数/页:   排序方式:
Repurposing of the FGFR inhibitor AZD4547 as a potent inhibitor of necroptosis by selectively targeting RIPK1 期刊论文
ACTA PHARMACOLOGICA SINICA, 2022
作者:  Wang, Zuo-wei;  Zou, Feng-ming;  Wang, Ao-li;  Yang, Jing;  Jin, Rui;  Wang, Bei-lei;  Shen, Li-juan;  Qi, Shuang;  Liu, Juan;  Liu, Jing;  Wang, Wen-chao;  Liu, Qing-song
收藏  |  浏览/下载:51/0  |  提交时间:2022/12/22
AZD4547  RIPK1  inhibitors  SIRS model  anti-necroptosis  
CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancers 期刊论文
ACTA PHARMACOLOGICA SINICA, 2022
作者:  Cao, Jiang-yan;  Qi, Shuang;  Wu, Hong;  Wang, Ao-li;  Liu, Qing-wang;  Li, Xi-xiang;  Wang, Bei-lei;  Ge, Juan;  Zou, Feng-ming;  Chen, Cheng;  Wang, Jun-jie;  Hu, Chen;  Liu, Jing;  Wang, Wen-chao;  Liu, Qing-song
收藏  |  浏览/下载:107/0  |  提交时间:2022/03/28
HER2  breast cancers  gastric cancers  irreversible inhibitor  drug resistance  
Pharmacologically inhibiting phosphoglycerate kinase 1 for glioma with NG52 期刊论文
ACTA PHARMACOLOGICA SINICA, 2020
作者:  Wang, Wen-liang;  Jiang, Zong-ru;  Hu, Chen;  Chen, Cheng;  Hu, Zhen-quan;  Wang, Ao-li;  Wang, Li;  Liu, Jing;  Wang, Wen-chao;  Liu, Qing-song
收藏  |  浏览/下载:64/0  |  提交时间:2020/11/26
PGK1  NG52  kinase inhibitor  Warburg effect  glioma  
Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway 期刊论文
ACTA PHARMACOLOGICA SINICA, 2020
作者:  Chen, Cheng;  Cheng, Chuan-dong;  Wu, Hong;  Wang, Zuo-wei;  Wang, Li;  Jiang, Zong-ru;  Wang, Ao-li;  Hu, Chen;  Dong, Yong-fei;  Niu, Wan-xiang;  Qi, Shuang;  Qi, Zi-ping;  Liu, Jing;  Wang, Wen-chao;  Niu, Chao-shi;  Liu, Qing-song
浏览  |  Adobe PDF(3476Kb)  |  收藏  |  浏览/下载:103/36  |  提交时间:2020/11/26
glioblastoma  osimertinib  temozolamide  MAPK-signaling pathway  MNK  eukaryotic translation initiation factor 4E